BioNTech SE (NASDAQ:BNTX) is one of the top high growth international stocks to buy right now. On September 10, BMO Capital analyst Evan Seigerman maintained a Buy rating on BioNTech SE (NASDAQ:BNTX), keeping the price target at $143.00.
The analyst stated that one of the primary reasons behind the optimistic rating is the anticipation of a stable COVID-19 vaccine business for BioNTech SE (NASDAQ:BNTX) in the near and medium term, potentially providing a strong revenue base.
Seigerman added that BioNTech SE (NASDAQ:BNTX) has an emerging pipeline with a number of catalysts that have the potential to drive share price appreciation, suggesting future growth.
BioNTech SE (NASDAQ:BNTX) is a German biotechnology company that creates messenger RNA (mRNA) therapeutics and vaccines to address serious diseases such as cancer and infectious diseases. It specializes in developing and manufacturing immunotherapies for patient-specific approaches.
While we acknowledge the potential of BNTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.